Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson's Disease Psychosis-Reference-Cited by-同舟云学术

Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson's Disease Psychosis

Published:2023-01-10 Issue:3 Volume:10 Page:406-414
ISSN:2330-1619
Container-title:Movement Disorders Clinical Practice
language:en
Short-container-title:Movement Disord Clin Pract

Author:

Alipour‐Haris Golnoosh¹,Armstrong Melissa J.²^ORCID,Okun Michael²,Brown Joshua D.¹

Affiliation:

1. Center for Drug Evaluation & Safety and The Department of Pharmaceutical Outcomes & Policy University of Florida College of Pharmacy Gainesville Florida USA

2. Norman Fixel Institute for Neurological Diseases and the Department of Neurology University of Florida College of Medicine Gainesville Florida USA

Funder

Florida Department of Health

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mdc3.13652

Reference30 articles.

1. Non-motor features of Parkinson disease

2. A 12-Year Population-Based Study of Psychosis in Parkinson Disease

3. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

4. Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson’s Disease Patients: A Population-Based Study

5. Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics;Journal of Comparative Effectiveness Research;2024-07

2. Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial;Journal of Alzheimer's Disease;2024-06-11

3. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine;Journal of Integrative Neuroscience;2024-04-12

4. Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson’s Disease Psychosis;ClinicoEconomics and Outcomes Research;2024-03

5. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis;Clinical Parkinsonism & Related Disorders;2024